A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with
Adult
Aged
Alanine Transaminase
/ blood
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Benzimidazoles
/ administration & dosage
Carbamates
/ administration & dosage
Drug-Related Side Effects and Adverse Reactions
/ classification
Female
Humans
Male
Melanoma
/ blood
Middle Aged
Mitogen-Activated Protein Kinase Kinases
/ antagonists & inhibitors
Protein Kinase Inhibitors
/ administration & dosage
Proto-Oncogene Proteins B-raf
/ antagonists & inhibitors
Sulfonamides
/ administration & dosage
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 10 2020
01 10 2020
Historique:
received:
29
10
2019
revised:
16
03
2020
accepted:
13
07
2020
pubmed:
17
7
2020
medline:
26
11
2021
entrez:
17
7
2020
Statut:
ppublish
Résumé
This open-label, dose-finding phase Ib/II study reports the safety and activity of the first combination use with BRAF inhibitor (BRAFi) encorafenib plus MEK inhibitor (MEKi) binimetinib in patients with In phase I, the recommended phase 2 doses (RP2D) were established (primary objective). In phase II, the clinical activity of the combination at the RP2D was assessed (primary objective) in patients with A total of 126 patients with The combination of encorafenib (450 mg) plus binimetinib (45 mg) showed acceptable tolerability and encouraging activity in patients with
Identifiants
pubmed: 32669376
pii: 1078-0432.CCR-19-3550
doi: 10.1158/1078-0432.CCR-19-3550
doi:
Substances chimiques
Benzimidazoles
0
Carbamates
0
Protein Kinase Inhibitors
0
Sulfonamides
0
binimetinib
181R97MR71
encorafenib
8L7891MRB6
Alanine Transaminase
EC 2.6.1.2
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Mitogen-Activated Protein Kinase Kinases
EC 2.7.12.2
Banques de données
ClinicalTrials.gov
['NCT01543698']
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5102-5112Informations de copyright
©2020 American Association for Cancer Research.